logo
logo
Sign in

Urinary Tract Infection Therapeutic Market Evolution: Embracing Personalized Therapies

avatar
Roger
Urinary Tract Infection Therapeutic Market Evolution: Embracing Personalized Therapies

Urinary tract infections (UTIs) are one of the most common types of infections in the urinary system. UTIs occur when bacteria enter the urethra or bladder through the urethra and multiply, causing symptoms such as pain or burning sensation while urinating, frequent urination in small amounts, and feeling the need to urinate despite having an empty bladder. The global urinary tract infection therapeutics aim to treat and cure UTIs by offering various treatment options such as antibiotics, vaccines, and others that help kill the bacteria causing infection or prevent new infections. The increasing awareness about UTIs and availability of various treatment options are driving the growth of the market.


The global Urinary Tract Infection Therapeutic Market is estimated to be valued at US$ 8,665.5 Mn in 2024 and is expected to exhibit a CAGR of 3.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.


Market Opportunity:

Increasing Healthcare Expenditure

The increasing healthcare expenditure across the globe, especially in developed economies is estimated to offer ample growth opportunities for the urinary tract infection therapeutics market over the forecast period. According to the U.S. Centers for Disease Control and Prevention (CDC), the total healthcare expenditure in the U.S. grew 4.6% to reach $3.8 trillion in 2019. Rising disposable income and increasing spending on healthcare is expected to drive the growth of the market. Improving access to healthcare facilities is also propelling the demand for various UTI treatment drugs and vaccines.


Porter’s Analysis


Threat of new entrants: The therapeutics segment requires heavy R&D investments and regulatory approvals pose high entry barriers.


Bargaining power of buyers: Buyers have moderate bargaining power due to the availability of generic drugs and treatment alternatives.


Bargaining power of suppliers: Large drug makers have significant bargaining power over API suppliers and contract manufacturing organizations.


Threat of new substitutes: Alternative treatment options and generic drugs pose substitution threats.


Competitive rivalry: Intense competition exists among existing players to gain higher market shares.


SWOT Analysis


Strength: Strong product pipeline and extensive research on novel drug formulations. Large player presence ensures established supply chains.


Weakness: High R&D investments and stringent regulatory norms increase costs of development. Generics pose pricing pressure on patented drugs.


Opportunity: Rising incidence of UTIs worldwide presents growth opportunities. Market demand in developing regions is increasing.


Threats: Side effects and emergence of antibiotic-resistant bacteria strains are major concerns. Regulatory uncertainty impacts product approvals.


Key Takeaways


The global urinary tract infection therapeutic market is expected to witness high growth over the forecast period. The rising prevalence of UTIs worldwide and lack of effective prevention measures will boost demand for therapeutic drugs. According to estimates, the Americas holds the largest share currently due to the strong presence of leading pharmaceutical players. The global Urinary Tract Infection Therapeutic Market is estimated to be valued at US$ 8,665.5 Mn in 2024 and is expected to exhibit a CAGR of 3.0% over the forecast period 2023 to 2030.


Regional analysis

The Asia Pacific region represents the fastest growing regional market for UTI therapeutics. Factors such as the increasing spending on healthcare infrastructure and rising awareness about infections are expected to drive the market in the region. China and India will likely emerge as highly lucrative country-level markets owing to the large patient population and improving access to diagnosis and treatment.


Key players

Key players operating in the urinary tract infection therapeutic market are Pfizer, Novartis AG, Cipla Inc., Bayer AG, AstraZeneca, Shionogi & Co. Ltd., and GlaxoSmithKline PLC, among others. Pfizer maintains a leading position through its diversified product portfolio for uncomplicated and complicated UTIs.


collect
0
avatar
Roger
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more